TW200500078A - Modified asialo-interferons and uses thereof - Google Patents
Modified asialo-interferons and uses thereofInfo
- Publication number
- TW200500078A TW200500078A TW092124573A TW92124573A TW200500078A TW 200500078 A TW200500078 A TW 200500078A TW 092124573 A TW092124573 A TW 092124573A TW 92124573 A TW92124573 A TW 92124573A TW 200500078 A TW200500078 A TW 200500078A
- Authority
- TW
- Taiwan
- Prior art keywords
- poly
- asialo
- interferons
- modified
- oxyethylated
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/565—IFN-beta
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/57—IFN-gamma
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US40836102P | 2002-09-05 | 2002-09-05 | |
US43114802P | 2002-12-05 | 2002-12-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
TW200500078A true TW200500078A (en) | 2005-01-01 |
Family
ID=31981589
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW092124573A TW200500078A (en) | 2002-09-05 | 2003-09-05 | Modified asialo-interferons and uses thereof |
Country Status (10)
Country | Link |
---|---|
US (1) | US20040136955A1 (zh) |
EP (1) | EP1549332A4 (zh) |
JP (1) | JP2006508918A (zh) |
KR (1) | KR20050083677A (zh) |
AU (1) | AU2003270341A1 (zh) |
CA (1) | CA2497777A1 (zh) |
HK (1) | HK1079995A1 (zh) |
MX (1) | MXPA05002476A (zh) |
TW (1) | TW200500078A (zh) |
WO (1) | WO2004021993A2 (zh) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5545553A (en) * | 1994-09-26 | 1996-08-13 | The Rockefeller University | Glycosyltransferases for biosynthesis of oligosaccharides, and genes encoding them |
AU751898B2 (en) * | 1997-07-14 | 2002-08-29 | Bolder Biotechnology, Inc. | Derivatives of growth hormone and related proteins |
US6753165B1 (en) * | 1999-01-14 | 2004-06-22 | Bolder Biotechnology, Inc. | Methods for making proteins containing free cysteine residues |
US20080076706A1 (en) * | 1997-07-14 | 2008-03-27 | Bolder Biotechnology, Inc. | Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof |
US8288126B2 (en) | 1999-01-14 | 2012-10-16 | Bolder Biotechnology, Inc. | Methods for making proteins containing free cysteine residues |
US7399613B2 (en) * | 2001-10-10 | 2008-07-15 | Neose Technologies, Inc. | Sialic acid nucleotide sugars |
US7795210B2 (en) | 2001-10-10 | 2010-09-14 | Novo Nordisk A/S | Protein remodeling methods and proteins/peptides produced by the methods |
US7696163B2 (en) | 2001-10-10 | 2010-04-13 | Novo Nordisk A/S | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
US7214660B2 (en) | 2001-10-10 | 2007-05-08 | Neose Technologies, Inc. | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
US7179617B2 (en) * | 2001-10-10 | 2007-02-20 | Neose Technologies, Inc. | Factor IX: remolding and glycoconjugation of Factor IX |
US8008252B2 (en) * | 2001-10-10 | 2011-08-30 | Novo Nordisk A/S | Factor VII: remodeling and glycoconjugation of Factor VII |
US7173003B2 (en) | 2001-10-10 | 2007-02-06 | Neose Technologies, Inc. | Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF |
US7157277B2 (en) | 2001-11-28 | 2007-01-02 | Neose Technologies, Inc. | Factor VIII remodeling and glycoconjugation of Factor VIII |
DE60336555D1 (de) | 2002-06-21 | 2011-05-12 | Novo Nordisk Healthcare Ag | Pegylierte glykoformen von faktor vii |
RU2005118752A (ru) * | 2002-11-15 | 2006-02-10 | Ф.Хоффманн-Ля Рош Аг (Ch) | Позиционные изомеры пэгилированного интерферона l-2а (конъюгата пэг-ifn-l-2а) |
BRPI0408358A (pt) | 2003-03-14 | 2006-03-21 | Neose Technologies Inc | polìmeros hidrossolúveis ramificados e seus conjugados |
WO2006127896A2 (en) | 2005-05-25 | 2006-11-30 | Neose Technologies, Inc. | Glycopegylated factor ix |
US8791070B2 (en) | 2003-04-09 | 2014-07-29 | Novo Nordisk A/S | Glycopegylated factor IX |
EP2338333B1 (en) | 2003-04-09 | 2017-09-06 | ratiopharm GmbH | Glycopegylation methods and proteins/peptides produced by the methods |
US7691603B2 (en) * | 2003-04-09 | 2010-04-06 | Novo Nordisk A/S | Intracellular formation of peptide conjugates |
ES2380093T3 (es) | 2003-05-09 | 2012-05-08 | Biogenerix Ag | Composiciones y métodos para la preparación de mutantes de glucosilación de la hormona del crecimiento humana |
US9005625B2 (en) | 2003-07-25 | 2015-04-14 | Novo Nordisk A/S | Antibody toxin conjugates |
US20080305992A1 (en) | 2003-11-24 | 2008-12-11 | Neose Technologies, Inc. | Glycopegylated erythropoietin |
US8633157B2 (en) | 2003-11-24 | 2014-01-21 | Novo Nordisk A/S | Glycopegylated erythropoietin |
US20080318850A1 (en) * | 2003-12-03 | 2008-12-25 | Neose Technologies, Inc. | Glycopegylated Factor Ix |
US20060040856A1 (en) | 2003-12-03 | 2006-02-23 | Neose Technologies, Inc. | Glycopegylated factor IX |
US7956032B2 (en) * | 2003-12-03 | 2011-06-07 | Novo Nordisk A/S | Glycopegylated granulocyte colony stimulating factor |
AU2005206796B2 (en) | 2004-01-08 | 2011-06-16 | Ratiopharm Gmbh | O-linked glycosylation of peptides |
WO2005074546A2 (en) | 2004-02-02 | 2005-08-18 | Ambrx, Inc. | Modified human growth hormone polypeptides and their uses |
AU2008201682B2 (en) * | 2004-02-02 | 2011-02-24 | Ambrx, Inc. | Modified human interferon polypeptides and their uses |
US20080300173A1 (en) | 2004-07-13 | 2008-12-04 | Defrees Shawn | Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1] |
EP1799249A2 (en) * | 2004-09-10 | 2007-06-27 | Neose Technologies, Inc. | Glycopegylated interferon alpha |
JP5948627B2 (ja) | 2004-10-29 | 2016-07-20 | レイショファーム ゲーエムベーハー | 線維芽細胞成長因子(fgf)のリモデリングと糖質ペグ化 |
TW200633718A (en) * | 2004-12-16 | 2006-10-01 | Applied Research Systems | Treatment of hepatitis c in the asian population |
EP2514757A3 (en) | 2005-01-10 | 2014-03-05 | ratiopharm GmbH | Glycopegylated granulocyte colony stimulating factor |
EP1866427A4 (en) * | 2005-03-30 | 2010-09-01 | Novo Nordisk As | MANUFACTURING PROCESS FOR THE PRODUCTION OF CULTIVE PEPTIDES IN CELL LINES OF INSECTS |
US9187546B2 (en) | 2005-04-08 | 2015-11-17 | Novo Nordisk A/S | Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants |
JP5414270B2 (ja) * | 2005-05-23 | 2014-02-12 | エスデイージー・インコーポレーテツド | インスリンを哺乳動物に送達するための脂質構築物 |
EP1888098A2 (en) | 2005-05-25 | 2008-02-20 | Neose Technologies, Inc. | Glycopegylated erythropoietin formulations |
US20070105755A1 (en) * | 2005-10-26 | 2007-05-10 | Neose Technologies, Inc. | One pot desialylation and glycopegylation of therapeutic peptides |
AU2006280932A1 (en) * | 2005-08-19 | 2007-02-22 | Novo Nordisk A/S | Glycopegylated factor VII and factor Vila |
WO2007056191A2 (en) | 2005-11-03 | 2007-05-18 | Neose Technologies, Inc. | Nucleotide sugar purification using membranes |
WO2008011633A2 (en) * | 2006-07-21 | 2008-01-24 | Neose Technologies, Inc. | Glycosylation of peptides via o-linked glycosylation sequences |
US20100075375A1 (en) | 2006-10-03 | 2010-03-25 | Novo Nordisk A/S | Methods for the purification of polypeptide conjugates |
WO2008073620A2 (en) * | 2006-11-02 | 2008-06-19 | Neose Technologies, Inc. | Manufacturing process for the production of polypeptides expressed in insect cell-lines |
KR20100016160A (ko) | 2007-04-03 | 2010-02-12 | 바이오제너릭스 에이지 | 글리코페길화 g―csf를 이용하는 치료 방법 |
US20090053167A1 (en) * | 2007-05-14 | 2009-02-26 | Neose Technologies, Inc. | C-, S- and N-glycosylation of peptides |
JP5876649B2 (ja) | 2007-06-12 | 2016-03-02 | ラツィオファルム ゲーエムベーハーratiopharm GmbH | ヌクレオチド糖の改良製造法 |
US8207112B2 (en) | 2007-08-29 | 2012-06-26 | Biogenerix Ag | Liquid formulation of G-CSF conjugate |
US8597635B2 (en) * | 2007-09-04 | 2013-12-03 | Biosteed Gene Expression Tech. Co., Ltd. | Interferon alpha-2B modified by polyethylene glycol and methods of preparation thereof |
WO2009108806A1 (en) | 2008-02-27 | 2009-09-03 | Novo Nordisk A/S | Conjugated factor viii molecules |
EA020220B1 (ru) * | 2011-12-21 | 2014-09-30 | Общество С Ограниченной Ответственностью "Форт" (Ооо "Форт") | Ковалентный конъюгат полиэтиленгликоля с полипептидом, имеющим активность интерферона-гамма |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU1234383A (en) * | 1982-03-17 | 1983-09-22 | Inter-Yeda Ltd. | Interferon stabilised with polyvinyl-pyrrolidone |
US4847325A (en) * | 1988-01-20 | 1989-07-11 | Cetus Corporation | Conjugation of polymer to colony stimulating factor-1 |
US5382657A (en) * | 1992-08-26 | 1995-01-17 | Hoffmann-La Roche Inc. | Peg-interferon conjugates |
US5349001A (en) * | 1993-01-19 | 1994-09-20 | Enzon, Inc. | Cyclic imide thione activated polyalkylene oxides |
US5359030A (en) * | 1993-05-10 | 1994-10-25 | Protein Delivery, Inc. | Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same |
HUT75533A (en) * | 1993-11-10 | 1997-05-28 | Schering Corp | Improved interferon polymer conjugates |
US5446090A (en) * | 1993-11-12 | 1995-08-29 | Shearwater Polymers, Inc. | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
US6296844B1 (en) * | 1995-09-27 | 2001-10-02 | The General Hospital Corporation | Asialocytokines and treatment of liver disease |
JPH11171788A (ja) * | 1997-12-11 | 1999-06-29 | Toray Ind Inc | C型肝細胞癌再発抑制剤 |
US7297511B2 (en) * | 2001-10-10 | 2007-11-20 | Neose Technologies, Inc. | Interferon alpha: remodeling and glycoconjugation of interferon alpha |
-
2003
- 2003-09-03 MX MXPA05002476A patent/MXPA05002476A/es not_active Application Discontinuation
- 2003-09-03 CA CA002497777A patent/CA2497777A1/en not_active Abandoned
- 2003-09-03 WO PCT/US2003/027835 patent/WO2004021993A2/en active Application Filing
- 2003-09-03 AU AU2003270341A patent/AU2003270341A1/en not_active Abandoned
- 2003-09-03 EP EP03752027A patent/EP1549332A4/en not_active Withdrawn
- 2003-09-03 KR KR1020057003869A patent/KR20050083677A/ko not_active Application Discontinuation
- 2003-09-03 US US10/654,796 patent/US20040136955A1/en not_active Abandoned
- 2003-09-03 JP JP2004534635A patent/JP2006508918A/ja not_active Withdrawn
- 2003-09-05 TW TW092124573A patent/TW200500078A/zh unknown
-
2006
- 2006-01-04 HK HK06100140.3A patent/HK1079995A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
JP2006508918A (ja) | 2006-03-16 |
AU2003270341A1 (en) | 2004-03-29 |
EP1549332A2 (en) | 2005-07-06 |
KR20050083677A (ko) | 2005-08-26 |
HK1079995A1 (zh) | 2006-04-21 |
EP1549332A4 (en) | 2008-06-18 |
US20040136955A1 (en) | 2004-07-15 |
AU2003270341A8 (en) | 2004-03-29 |
MXPA05002476A (es) | 2005-10-19 |
WO2004021993A3 (en) | 2004-06-24 |
CA2497777A1 (en) | 2004-03-18 |
WO2004021993A2 (en) | 2004-03-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW200500078A (en) | Modified asialo-interferons and uses thereof | |
GEP20084486B (en) | Polymer conjugates of interferon-beta with enhanced biological potency | |
HK1092485A1 (en) | Method of manufacture of polyacrolein | |
MXPA02003540A (es) | Derivados de poli(etilenglicol) heterobifuncionales y los metodos para su preparacion. | |
EA200602137A1 (ru) | Гидрогелевые препараты интерферона | |
DE602005013504D1 (en) | Hydrophile materialien aus oligomeren mit photoinitiator-gruppen | |
RS20070365A (en) | Gastroresistant pharmaceutical formulations containing rifaximin | |
BRPI0514293A (pt) | sais de dicetopiperazina, sais de dicetomorfolina ou sais de dicetodioxano para administração de droga | |
WO2005018530A3 (en) | Penetrating pharmaceutical foam | |
MX249657B (es) | Copolimeros elaborados de oxidos de alquileno y glicidil eteres y su uso como emulsionantes polimerizables. | |
SE0200207D0 (sv) | Chain extended dendritic polyether | |
WO2000040203A3 (en) | Polymeric delivery agents and delivery agent compounds | |
ATE328028T1 (de) | Pharmazeutische zusammensetzung enthaltend polyalkylenoxide mit verringerten mengen an ameisensäure und ameisensäurederivaten | |
NZ507350A (en) | Semi-synthetic ecteinascidins and use in treatment of tumors | |
WO2006019950A3 (en) | Conjugates of a gm-csf moiety and a polymer | |
BR0111139B1 (pt) | utilizaÇço de pelo menos uma hidrotalcita, composiÇço de polÍmero, artigo acabado, e, pneumÁtico. | |
WO2000066528A3 (en) | Quinones for treatment of diseases | |
DE60320224D1 (de) | Hydrolytisch abbaubare polyalkylenoxid-polymere | |
CY1105142T1 (el) | Χρηση υποκατεστημενων ενωσεων 6-διμεθυλαμινομεθυλο-1-φαινυλο-κυκλοεξανιου για τη θepαπεια της ακρατειας ουρων | |
TR200302134T4 (tr) | 2-metil-tiazolidin-2,4-dikarboksilik asit ve/veya bunun fizyolojik olarak uygun tuzlarının anti-kanser ajanları olarak kullanımı. | |
WO2001068676A3 (de) | Lh-rh-antagonisten, deren herstellung und verwendung als arzeimittel | |
FI990140A0 (fi) | Korkea-aktiivinen olefiinipolymerointikatalysaattori, sen valmistus, katalysaattorisysteemi ja käyttö | |
ITRM20010048A0 (it) | Metodo per preparare soluzioni acquose fisiologicamente accettabili esoluzioni cosi' ottenute. | |
MY150767A (en) | Polyethylene glycol modifications of thymosin alpha 1 | |
EP1574507A3 (en) | Furo- and pyrano-naphthoquinones and their use in the treatment of cancer |